Supplementary file 1. The protocol article entitled "Clostridioides difficile infection in frail older patients, quality in treatment and care: the CLODIFRAIL study protocol for a multicentre randomised controlled trial"

4

5 *Clostridioides difficile* infection in frail older patients, quality in treatment and care: the CLODIFRAIL 6 study protocol for a multicentre randomised controlled trial

- 7
- 8 Tone Rubak^{1,2}, Hanne Veilbæk¹, Merete Gregersen^{1,2}, Malene Asferg³, Ishay Barat⁴, Joanna Johnsen⁵, Mikael
- **9** Groth Riis⁶, Jeppe Bakkestrøm Rosenbæk⁷, Marianne Ørum¹, Rita Stockholm Vinding⁸, Carl Aksel Kragh

10 Sørensen⁹, Claire J Steves¹⁰, Simon Mark Dahl Baunwall^{2,11}, Christian Lodberg Hvas^{2,11}, Else Marie Skjøde

- 11 Damsgaard^{1,2}
- 12
- 13 ¹Department of Geriatrics, Aarhus University Hospital, Denmark
- 14 ²Department of Clinical Medicine, Aarhus University, Denmark
- 15 ³Department of Geriatrics, Medical Department, Silkeborg Regional Hospital, Denmark
- 16 ⁴Department of Geriatrics, Medical department, Horsens Regional Hospital, Denmark
- 17 ⁵Department of Geriatrics, Medical Department, Viborg Regional Hospital, Denmark
- 18 ⁶Department of Geriatrics, Medical Department, Randers Regional Hospital, Denmark
- **19** ⁷Department of Geriatrics, Medical Department, Gødstrup Regional Hospital, Denmark
- 20 ⁸Patient and Public Involvement group, Danish Council of senior citizens, Syddjurs, Denmark
- 21 ⁹Patient and Public Involvement group, Danish Council of senior citizens, Aarhus, Denmark
- 22 ¹⁰Department of Ageing and Health, Guy's and St Thomas' NHS Foundation Trust and Department of Twin Re-
- 23 search and Genetic Epidemiology, King's College London, United Kingdom
- 24 ¹¹Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark
- 26 Running title: Clostridioides difficile infection and frailty, the CLODIFRAIL study
- 27

25

28 Correspondence

- 29 Tone Rubak, MD, Department of Geriatrics, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-
- 30 8200 Aarhus N, email toneruba@rm.dk, telephone +45 78461933.
- 31
- 32 ORCID ID: Tone Rubak (0000-0003-4496-391X); Hanne Veilbæk (0009-0009-8862-3133): Merete Gregersen
- 33 (0000-0002-5365-7335); Malene Asferg (0009-0009-2423-135X); Ishay Barat (0009-0005-1590-8649); Joanna
- 34 Johnsen (0000-0001-7396-0369); Mikael Groth Riis (0009-0000-6532-7758); Jeppe Bakkestrøm Rosenbæk
- 35 (0000-0002-7863-0016); Marianne Ørum, (0000-0002-3578-5296); Rita Stokholm Vinding (0009-0002-5976-
- 36 0306); Carl Aksel Kragh Sørensen, (0000-0003-0561-5066); Simon Mark Dahl Baunwall (0000-0002-5135-
- 37 7435); Christian Lodberg Hvas (0000-0001-7973-7184); Else Marie Skjøde Damsgaard (0000-0001-5499-
- **38** 4731).
- 39

40 Abstract

41 Background: *Clostridioides difficile* infection (CDI) is complex and associated with adverse clinical outcomes 42 in older patients, including increased mortality rates. Effective transition of care for patients with CDI is critical 43 to improve survival and health outcomes and to reduce recurrence rates. This study aimed to investigate the ef-44 fect of a geriatric intervention on the survival of older patients with CDI compared with those receiving standard 45 care.

Methods and analysis: This is a quality improvement study comparing two organisational pathways. We plan to
include 216 patients aged 70 years or more diagnosed with CDI. Patients with a positive *Clostridioides difficile*toxin polymerase chain reaction (PCR) test are randomised 1:1 to either 1) a geriatric assessment and intervention (the CLODIFRAIL intervention) or 2) standard care at the treating physician's discretion. The intervention
has three main parts: 1) a clinical geriatric assessment; 2) a clinical evaluation of indication for and treatment

51 with faecal microbiota transplantation (FMT); 3) weekly clinical assessments during eight weeks. The follow-up

52 period is 90 days. The primary outcome is 90-day survival from the date of positive CDI PCR test.

53 Ethics and dissemination: The trial is conducted in accordance with the Declaration of Helsinki and poses no

54 project-related risks, experimental treatments, or invasive biological sample collection. The study is conducted

as a quality improvement study, embedded in two parallel and fundamentally different routine clinical care path-

56 ways. The study design and its categorisation as a quality improvement study is approved by the Central Den-

57 mark Region Committees on Health Research Ethics. This study will provide new knowledge on the effects of a

58 geriatric intervention for older patients with CDI, incorporating an early assessment of the indication for FMT on

59 patient survival and clinical outcomes.

60 Trial registration: The study was pre-registered at ClinicalTrials.gov on 28 June, 2022. Study identifier:

61 NCT05447533.

62 Keywords: Clostridioides difficile; Frailty; Aged; Faecal microbiota transplantation; Gastroenterology

63

64 Strengths:

- The project is innovative in aiming to improve care and treatment for all older patients with *Clostridioi- des difficile* infection in a real-life setting
- All patients with a positive *C. difficile* test are included and therefore, the population is representative of
 a broad range of older patients with *Clostridioides difficile* infection.

70 Limitations:

71	•	Standard care may include elements of the intervention during the follow-up period (geriatric care and
72		FMT), making it less likely that the intervention will produce any effects.
73	•	Component disaggregation for geriatric intervention is challenging, hindering replication precision.

75 Introduction

Clostridioides difficile infection (CDI) has a poor prognosis, and mortality rates increase dramatically with age.¹
 Treatment and care are managed across multiple healthcare settings, and this challenges the overall health care

78 management process.² Preventive strategies and effective therapeutic approaches are warranted to reduce older
79 patients' risk of dying from CDI.

80 CDI primarily affects older patients.³ Older patients with severe CDI are characterised by a high comorbidity

81 burden, low functional status, high degree of polypharmacy, malnutrition and a need for support in everyday

82 life.⁴⁻⁶ Collectively, these factors indicate frailty. Frailty is a framework used in geriatrics to describe older pa-

83 tients' risk of a poor prognosis. It develops due to age-related decline in physiological functions,⁷ collectively

84 increasing vulnerability to stressors.⁸ Previous studies indicate that CDI affects frail patients.⁹ Frailty indicators,

85 rather than age alone, are therefore important determinants of CDI risk in an older adult population.¹⁰

Frail older patients present with atypical symptoms¹¹, and typical symptoms of illness may change or be ab-

87 sent.¹²⁻¹⁴ The traditional CDI severity markers are not necessarily present in older patients.¹⁵ This challenges the

88 CDI severity assessment and may delay appropriate treatment initiation.¹⁶

Geriatricians are trained in the assessment and planning of care for multimorbid older patients. The Comprehensive Geriatric Assessment (CGA) is considered the gold standard of multidisciplinary assessment and care planning for this group.¹⁷ It is a diagnostic process intended to determine an older person's medical, psychosocial, and functional capacities and problems to create an overall treatment plan with short- and long-term followup, ultimately guiding intervention.¹⁸ Frailty identification and assessment are important constituent parts of the CGA. The Multidimensional Prognostic Index (MPI) is a systematic CGA-based assessment tool for prediction of short- and long-term mortality in older hospitalised patients.^{19,20}

96 Systematic reviews have affirmed the clinical utility of CGA-guided interventions for older patients com-

97 pared with standard care, including improved functional ability,²¹⁻²³ reduced mortality^{22,24} and increased survival

98 at home after discharge.²⁵ This was documented in the setting of in-hospital medical patients in dedicated ageing

99 and health wards and across different departments and medical conditions.^{25,26} In a Danish older adult inpatient

100 population, early geriatric follow-up conducted by outgoing geriatric teams after discharge reduced readmission

101 rates²⁷⁻²⁹ and mortality rates in such patients living in their own homes.³⁰

102 The need for transition of care for patients with CDI has been emphasized by others.² Older patients with

103 CDI are often diagnosed and managed across multiple health care settings and discharged prior to completion of

104	CDI therapy without follow-up, which increases their risk of recurrence, readmission and death. There is cur-
105	rently no existing literature regarding CGA and geriatric follow-up treatment at home for older patients with
106	CDI.
107	Faecal microbiota transplantation (FMT) has emerged as a life-saving treatment in patients with CDI. For
108	first and recurrent CDI, it is effective in achieving sustained resolution, ^{31,32} and it tends to reduce mortality rates
109	compared with vancomycin treatment alone. ³³ Limited data support that FMT has a similar effect and safety pro-
110	file in patients aged \geq 65 years. ³⁴⁻³⁷ Despite its benefits to this population at risk of recurrence and severe dis-
111	ease, 37 access to this treatment remains limited for older patients. In most settings, FMT requires hospital attend-
112	ance. Older patients who are too frail to tolerate transportation may therefore be withheld treatment. We previ-
113	ously proposed that FMT may be conducted as a hospital-at-home treatment, but this has yet to be confirmed in
114	larger scale. ³⁸
115	
116	Aim
117	The aim of this study is to investigate the effect of a geriatric intervention on the survival of older patients with
118	CDI compared with those receiving standard care.
119	
120	Methods
121	Study design
122	This is a multicentre randomised controlled trial (RCT) named CLOstridioides Difficile Infection in FRAIL older
123	patients (CLODIFRAIL). Outcomes are assessed after 90 days of follow-up. The patient flow is illustrated in
124	Figure 1; the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT), ³⁹ in Figure 2. The
125	SPIRIT checklist is included in Additional file 1.
126	
127	Roles and responsibilities
128	The study is conducted at Aarhus University Hospital, Denmark, and at four affiliated regional hospitals in the
129	Central Denmark Region (CDR). The study compares two well-known organisations of care and does not in-
130	volve experimental treatments or sampling of biological material beyond material obtained as part of routine
130 131	volve experimental treatments or sampling of biological material beyond material obtained as part of routine care. It is therefore classified as a quality improvement project and does not require patient consent before ran-
131	care. It is therefore classified as a quality improvement project and does not require patient consent before ran-

134	on research and development of FMT. ⁴⁰ The geriatricians in the medical departments in the CDR are responsible
135	for patient treatment and clinical contacts to patients. The organisation chart is illustrated in Additional file 2.
136	
137	Patient and public involvement
138	Two members of the Danish Council of senior citizens are engaged in the project steering group as patient repre-
139	sentatives (Additional file 2). The patient representatives have actively participated in the initial idea phase,
140	study planning, protocol review, development of information materials and offering assistance in securing fund-
141	ing for the study (Additional file 3).
142	
143	Study population
144	Eligible patients are consecutively included from a complete list of all patients in the CDR diagnosed with a pos-
145	itive Clostridioides difficile (CD) toxin polymerase chain reaction (PCR) test. The list is maintained at the De-
146	partment of Clinical Microbiology at Aarhus University Hospital and is sent to the project manager every week-
147	day. Patients are identified via the national identification number-based Civil Registration Register, collected and
148	managed using REDCap electronic data capture tools hosted at Aarhus University.41
149	Patient inclusion criteria
150	• Patients aged \geq 70 years and living in the CDR
151	• Positive PCR toxin test for CD
152	• Not previously included in the study during the study period
153	Patient exclusion criteria
154	• Patients already receiving geriatric assessment of CDI within 8 weeks from positive PCR test, defined
155	as follows: affiliated with the ageing and health wards (in- or outpatient activity) at the time of the posi-
156	tive PCR test for CDI
157	• FMT treatment 8 weeks before date of positive PCR test for CDI
158	• >4 episodes of CDI
159	• End-of-life care defined as follows: end-of-life care treatment has been initiated before positive PCR
160	test for CDI and the patient has a life expectancy less than days/few weeks, based on investigator con-
161	sensus.
162	Patients included are patients not already receiving parts of the intervention, including geriatric assessment
163	and/or FMT treatment. Only a few patients survive 4 or more episodes with CDI (unpublished data). Patients

164	with multiple recurrent CDI are refractory to any treatment and would therefore pose a special challenge. We
165	have chosen to exclude these patients as clinical experience indicates that these patients differ from the rest of
166	the population with CDI.
167	
168	Randomisation and blinding
169	Eligible patients are identified consecutively from the reporting system by the project manager and will be ran-
170	domised within the first weekday from a positive CD test. When the patient is allocated for geriatric intervention,
171	the project manager will contact the regional ageing and health wards who will contact the department that or-
172	dered the PCR test and plan a visit to the patient. Randomisation allocation will be performed in REDCap. Allo-
173	cation lists are generated for the treatment groups at a 1:1 ratio. Proper randomisation concealment was obtained
174	by use of an external randomisation service (Clinical Trial Unit, Department of Clinical Medicine, Aarhus Uni-
175	versity, Denmark).
176	The research assistant, who provides all the assessments at follow-up, is blinded with respect to allocation.
177	Given the nature of the intervention, it is not feasible to blind either the patients or the clinicians.
178	
178 179	Geriatric intervention
	<i>Geriatric intervention</i> The geriatric intervention is called the CLODIFRAIL intervention. It includes a systematic assessment of both
179	
179 180	The geriatric intervention is called the CLODIFRAIL intervention. It includes a systematic assessment of both
179 180 181	The geriatric intervention is called the CLODIFRAIL intervention. It includes a systematic assessment of both the patient's geriatric problems (CGA) and a systematic assessment of CDI-related symptoms, including an early
179 180 181 182	The geriatric intervention is called the CLODIFRAIL intervention. It includes a systematic assessment of both the patient's geriatric problems (CGA) and a systematic assessment of CDI-related symptoms, including an early assessment of indication for FMT. The intervention will be performed at the time of CDI diagnosis and includes
179 180 181 182 183	The geriatric intervention is called the CLODIFRAIL intervention. It includes a systematic assessment of both the patient's geriatric problems (CGA) and a systematic assessment of CDI-related symptoms, including an early assessment of indication for FMT. The intervention will be performed at the time of CDI diagnosis and includes an organised set of contacts to ensure close evaluation of clinical status and early intervention in case of exacer-
179 180 181 182 183 184	The geriatric intervention is called the CLODIFRAIL intervention. It includes a systematic assessment of both the patient's geriatric problems (CGA) and a systematic assessment of CDI-related symptoms, including an early assessment of indication for FMT. The intervention will be performed at the time of CDI diagnosis and includes an organised set of contacts to ensure close evaluation of clinical status and early intervention in case of exacerbation (Figure 3).
179 180 181 182 183 184 185	The geriatric intervention is called the CLODIFRAIL intervention. It includes a systematic assessment of both the patient's geriatric problems (CGA) and a systematic assessment of CDI-related symptoms, including an early assessment of indication for FMT. The intervention will be performed at the time of CDI diagnosis and includes an organised set of contacts to ensure close evaluation of clinical status and early intervention in case of exacerbation (Figure 3). The CLODIFRAIL intervention consists of the following components:
179 180 181 182 183 184 185 186	The geriatric intervention is called the CLODIFRAIL intervention. It includes a systematic assessment of both the patient's geriatric problems (CGA) and a systematic assessment of CDI-related symptoms, including an early assessment of indication for FMT. The intervention will be performed at the time of CDI diagnosis and includes an organised set of contacts to ensure close evaluation of clinical status and early intervention in case of exacer- bation (Figure 3). The CLODIFRAIL intervention consists of the following components: 1. CGA, including frailty assessment by the bedside MPI ¹⁹
179 180 181 182 183 184 185 186 187	The geriatric intervention is called the CLODIFRAIL intervention. It includes a systematic assessment of both the patient's geriatric problems (CGA) and a systematic assessment of CDI-related symptoms, including an early assessment of indication for FMT. The intervention will be performed at the time of CDI diagnosis and includes an organised set of contacts to ensure close evaluation of clinical status and early intervention in case of exacer- bation (Figure 3). The CLODIFRAIL intervention consists of the following components: 1. CGA, including frailty assessment by the bedside MPI ¹⁹ 2. Geriatric CDI check list, including geriatric evaluation of indication for FMT
179 180 181 182 183 184 185 186 187 188	The geriatric intervention is called the CLODIFRAIL intervention. It includes a systematic assessment of both the patient's geriatric problems (CGA) and a systematic assessment of CDI-related symptoms, including an early assessment of indication for FMT. The intervention will be performed at the time of CDI diagnosis and includes an organised set of contacts to ensure close evaluation of clinical status and early intervention in case of exacer- bation (Figure 3). The CLODIFRAIL intervention consists of the following components: 1. CGA, including frailty assessment by the bedside MPI ¹⁹ 2. Geriatric CDI check list, including geriatric evaluation of indication for FMT 3. Treatment with FMT if this is indicated
179 180 181 182 183 184 185 186 187 188 189	The geriatric intervention is called the CLODIFRAIL intervention. It includes a systematic assessment of both the patient's geriatric problems (CGA) and a systematic assessment of CDI-related symptoms, including an early assessment of indication for FMT. The intervention will be performed at the time of CDI diagnosis and includes an organised set of contacts to ensure close evaluation of clinical status and early intervention in case of exacer- bation (Figure 3). The CLODIFRAIL intervention consists of the following components: 1. CGA, including frailty assessment by the bedside MPI ¹⁹ 2. Geriatric CDI check list, including geriatric evaluation of indication for FMT 3. Treatment with FMT if this is indicated

192 Within five weekdays from the date of randomisation, the patients receive a visit by a physician trained in geriat-

- 193 ric medicine. A CGA with a tailor-made intervention will be conducted at the location where the patient is situ-
- 194 ated at the time of positive PCR test, i.e., in the allocated ward or at home. Relevant blood analyses are ordered
- if not already available (electrolytes, renal function, nutritional indicators, infectious parameters and haematolog-
- ical tests). Bedside evaluation of frailty will be conducted, using the MPI¹⁹ and registered in the Electronic Medi-
- cal Record (EMR). The MPI is a systematic CGA-based aggregate risk score based on comorbidity, habitation
- 198 status, number of daily prescription drugs used, activities of daily living, cognitive status, wound pressure score
- and nutritional risk. The MPI provides a tripartite score, categorising patients into groups of non-frail (MPI score
- 200 0.0-0.3; MPI=1), moderately frail (MPI score 0.34-0.66; MPI=2) and severely frail (MPI score 0.67-1.0;
- 201 MPI=3)¹⁹. An individualised intervention will be performed according to the clinical issues identified.
- 202
- 203 2. Geriatric CDI checklist and early assessment of FMT indication

The geriatric CDI checklist (Figure 4) will be performed by the geriatrician at the first visit to secure early CDI

assessment and prepare a treatment strategy. The checklist will be uploaded to the electronic archive of the

EMR. The procedure implies a geriatric evaluation of indication for FMT and treatment planning. CDI-related

symptoms are reported in the EMR using standardised headlines (Additional file 4). The checklist recommends

to start vancomycin treatment 125 mg x 4 on the same day as the positive PCR test for CDI has been received, if

209 indicated. Next, the checklist recommends to revise the medication list, in particular by discontinuing antibiotics

and proton pump inhibitors, if possible, as well as optimising the patient's nutritional and hydration status ac-

211 cording to our national guidelines.⁴² FMT will be considered if the patient fulfils one of the following criteria:

212 1) Severe index, recurrent or refractory CDI as defined by national clinical guidelines⁴³

213

or

214 2) High-risk patient defined as frailty grade MPI-2 (moderate) or MPI-3 (severe).

215 If FMT is indicated, a date for the FMT procedure will be scheduled. Information material (Additional file 5)

targeting CDI and treatment will be delivered to the patient. Targeted CDI information for primary health care

will be ensured through corresponding letters, using standardised headlines (Additional file 4).

218

219 3. Treatment with faecal microbiota transplantation

220 When the patient meets the indication for FMT, FMT will be performed at hospital or at home. FMT will be de-221 livered as 15-25 capsules (\sim 50 grams of donor faeces from one thoroughly screened healthy donor ⁴⁴). If the pa-222 tient has dysphagia diagnosed by dysphagia screening or carries a nasogastric tube, vancomycin and FMT can be 223 delivered by naso-jejunal tube (Bengmark 10 Fr, Nutricia), requiring referral to the Radiology Department for 224 verification of duodenal/jejunal tube placement. If the patient cannot come to the hospital for control of place-225 ment of the naso-jejunal tube, FMT can be delivered by a nasogastric tube under close clinical monitoring. Each 226 FMT component is accompanied by a treatment leaflet and a patient consent form. The treatment leaflet ensures 227 traceability between each unique FMT component and recipient. It contains the recipient's name and national 228 identification number-based Civil Registration Register, FMT information and anonymised donor data. It is 229 completed by the attending physician at each FMT. If the patient is not admitted to hospital, FMT can be deliv-230 ered as home treatment via a regional geriatric team or the project manager and project nurse (Additional files 6 231 and 7).

232

233 *4. Clinical contacts*

234 Physicians arrange weekly telephone contact and schedule the necessary clinical contacts within the project pe-235 riod. Clinical contacts can encompass a clinical evaluation, further drug adjustments, blood tests, etc., and can be 236 conducted by a geriatrician and/or a geriatric nurse or through telephone contacts with the patient, a relative or 237 the home nursing service. To secure clinical symptom feedback on treatment, patients and/or relatives or home 238 nursing service personnel are asked to fill out stool diary, including Bristol scale (Additional file 8) and return 239 the answers in a standardised form (Additional file 4, "Corresponding letter for primary health care"), which is 240 documented in the EMRs. The ageing and health wards remain responsible for CDI treatment for a minimum of 241 8 weeks from the last FMT or start of antibiotic CDI treatment and until CDI resolution. A control stool PCR test 242 for CDI will be performed upon treatment termination.

243 Upon FMT treatment termination, we will ensure continued cooperation with the primary sector by incorpo-244 rating standardised headlines in the discharge summary describing the treatment status and any precautionary

- 245 principles for future treatment (Additional file 4).
- 246

247 *Procedures for monitoring intervention adherence*

To secure adherence to the intervention, all activities will be logged in the patient's EMR, including the MPI, theCDI checklist and FMT.

251	Standard care group
252	Patients are not contacted by the geriatric team until after 90 days of follow-up but can be admitted and/or re-
253	ferred to ageing and health wards by their patient care team during the entire period. They receive usual treat-
254	ment at the treating physician's discretion. The Danish healthcare system is tax-financed and available to all
255	Danish residents on a free and equal basis. The general practitioner functions as a gatekeeper to the secondary
256	sector. In the CDR, Aarhus University Hospital and the four main regional hospital units provide secondary car
257	(outpatient, inpatient and intensive care). Standard care includes assessment of CDI and treatment with CDI-re-
258	lated antibiotics and FMT if the physician finds that this is indicated. All patients can be referred to FMT as an
259	outpatient clinic activity or during admission. Standard care for patients with CDI in Denmark is described in th
260	national clinical guideline. ⁴²
261	
262	Outcome measures
263	All outcome measures are predefined and will be registered at 90 days (\pm 7 days) from the date of positive PCR
264	test for CDI.
265	The primary outcome is 90-day survival from the date of positive PCR test for CDI.
266	Secondary outcomes include quality improvement-related and patient-related outcomes:
267	1. Quality- related outcome measures
268	a. Time-to-treatment with FMT. Time frame: from date of positive PCR test for CD to date of FMT.
269	b. Time-to-treatment with vancomycin. Time frame: from date of positive PCR test for CD to date of
270	start treatment with vancomycin.
271	c. CDI recurrence within a 90-day follow-up period. Recurrent CDI is defined as a new CDI episode af
272	ter ended CDI treatment with treatment response. New episode of diarrhoea (≥3 loose stools, Bristol
273	6-7) and a positive CD toxin test.
274	d. Readmission defined as any unplanned, acute rehospitalisation (elective or planned admissions and
275	outpatient procedures excluded) at any hospital within the CDR, occurring within four hours and up
276	30 days after hospital discharge. ⁴⁵
277	e. Days in hospital: number of days in hospital from date of first positive PCR/inclusion in study and
278	until 90 days. Both dates are included.
279	2. Patient related outcomes

- a. Quality of life measured by the European Quality of Life (EuroQol) measurement of health-related quality
- of life⁴⁶ (version of the European Quality of Life-5 Domain (EQ-5D-5L) Interviewer Administration and EQ-
- 5D-5L proxy 2) and by the Overall Quality of Life Depression List (OQoL-DL)⁴⁷
- b. Functional status is measured by the Functional Recovery Score (FRS)⁴⁸
- 284 Mortality is chosen as the primary outcome and quality of life and functional capacity as a secondary out-
- 285 come by consensus in the project steering group. Overall QoL is assessed by the OQoL-DL because of its ac-
- 286 ceptable level of agreement and reliability in frail older persons with moderate cognitive impairment ⁴⁷. The
- 287 OQoL-DL is supplemented by the EQ-5D,^{46,49} which is intended to complement other QoL measures and to fa-
- 288 cilitate collection of a common data set for reference purposes. It is a generic health-related QoL instrument that
- has been used to describe population health and health outcomes in clinical trials. Five dimensions are mapped:
- 290 mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The version EQ-5D-5L paper inter-
- viewer administration and the EQ-5D-5L proxy version will be performed.
- 292 The FRS⁴⁸ consists of a refined Katz Index⁵⁰ and Lawton Scale⁵¹ and includes mobility assessment (Activi-
- ties of Daily Living (ADL)+ I-ADL), resulting in an instrument that has five (ADL) and six (I-ADL) options for
- assessing each item. ADL and mobility comprise 77% of the FRS score; I-ADL, 23%. It has predictive and dis-
- criminant validity and is responsive to changes.
- 296

297 Data collection, management and analysis

- 298 Baseline variables
- 299 The following descriptive variables are registered at baseline:
- 300 Demographic data
- 301 Charlson Comorbidity Index⁵²
- 302 Frailty level measured by record-based MPI⁵³
- 303 CDI diagnosis, site (primary healthcare, outpatient, inpatient)
- 304 CD toxin profile
- 305 CDI definition⁵⁴ Healthcare facility-onset, Community-onset, Healthcare facility-associated, Community-asso-
- 306 ciated
- 307 Faecal chart consistency and frequency will be registered for the intervention group
- 308 Habitation status (Living in own home, Nursing home resident)

- Use of antibiotics (other than CDI related antibiotics) at time of positive PCR test for CDI and within one

310 month before date of positive PCR test for CDI

311 - Use of proton-pump inhibitors at time of positive PCR test for CDI

312 Measuring QoL and functional capacity at baseline is not feasible because this could possibly affect the standard

- 313 care group, which is intended to receive no interaction from the geriatric team until the follow-up date.
- 314

315 Data collection

316 Data are collected and managed using REDCap electronic data capture tools hosted at Aarhus University to se-317 cure data security and storage.⁴¹ The database includes range checks for data values. To avoid double data en-318 tries, the national identification number-based Civil Registration Register is checked before data entrance. Base-319 line characteristics are obtained from the EMRs only, and will be collected before randomisation. Primary out-320 come and quality-related outcome measures will be obtained from the EMRs. The project manager will collect 321 all data from the EMRs. Collection of data on primary outcome will also be checked by a specialist in either ger-322 iatric or gastrointestinal diseases to avoid errors. The project manager has access to all EMRs in the CDR. 323 FRS, OQoL-DL and EQ-5D-5L tests will be performed on both groups by a trained project assistant during 324 planned home visits. Additionally, the FRS will be performed retrospectively on both groups, including record-

325 ing of functional capacity before CDI at the date of positive CDI PCR test.

326

327 Sample size calculation

328 Sample size calculation: 90-day mortality rate in CDI patients aged \geq 70 years is 32% according to our cohort 329 study (unpublished data) and another European study.¹ Hence, the 90-day mortality rate for the standard care 330 group was set to 32%. The assumed effect of the intervention was calculated on the basis of the 12% 90-day 331 mortality rate among CDI patients receiving FMT⁵⁵ and the 20% mortality rate in geriatric patients receiving CGA.²⁹ However, in Hocquart's study,⁵⁵ a sixth of the patients are below the age of 70 years. Therefore, the 12% 332 333 mortality rate might be underestimated. Furthermore, Hansen et al.²⁹ performed CGA only on moderate to se-334 verely frail patients. As we will include patients also with mild frailty, the 90-day mortality rate of 20% might be 335 overestimated. Assuming an additive effect of CGA on FMT interventions, a mortality rate between 12% and 336 20% is considered realistic, with an estimated rate of 15%. Consequently, the expected mortality difference 337 would be 17% (32%-15%). With a power of 80% and an alpha of 5%, 108 patients are needed in each group;

338 which is the final number of patients, not taking into account drop-outs. We have predetermined an interim anal-

339 ysis to be conducted after enrolling 108 randomised patients, with predefined stopping rules based on the

Haybittle-Peto limits, which require statistical significance levels below 0.001.⁵⁶ The analysis will be performed
by a blinded external reviewer.

342

343 Statistical analysis plan

The statistical analysis will be performed by the project manager and members of the team when the last patient has completed the follow-up period and all data have been entered into REDCap. Patients' baseline characteristics will be compared using chi-square test or Fisher's exact tests for categorical variables and Wilcoxon Rank Sum test or Student's t-test for continuous variables, as appropriate.

348 Primary outcome analyses of 90-day mortality will be performed according to the intention-to-treat and per-349 protocol principles. The per-protocol analysis will include all patients who have undergone their first visit, which 350 includes assessment of the multidimensional prognostic index and completion of the CDI checklist. The binary 351 primary outcome will be tested for significance in a binary regression model and presented as an odds ratio (OR) 352 estimate with 95% confidence intervals (CIs). Estimates will be provided with 95% exact confidence intervals 353 and medians with interquartile ranges or ranges, as applicable. Precision will be performed by adjusting for age \geq 354 85 years (yes/no) and diagnosed during hospital admission (yes/no). Furthermore, subgroup analysis of the two 355 stratified groups (age \geq 85 years (yes/no) and diagnosed during hospital admission (yes/no)) will be performed 356 according to binary primary outcome and presented as OR. The OR for patients diagnosed during hospital ad-357 mission will be compared with the OR of patients diagnosed outside hospital. Likewise, the RR of patients aged 358 \geq 85 years will be compared with the OR of patients < 85 years. We will conduct an as-treated-analysis of the 359 primary outcome, comparing patients receiving FMT within 90 days from positive PCR test for CDI compared 360 with those who did not. The primary outcome will be tested for significance using chi-square test, and OR will 361 be estimated using the binary regression model.

Secondary outcomes: Recurrent CDI and readmission will be tested for statistical significance in a binary regression model. Functional status (estimated by FRS sum score) and overall QoL (estimated by EQ-5D-5L and OQoL-DL sum scores) in the survivors on day 90 will be compared in a linear regression model. Precision will be assessed by adjusting for age \geq 85 years (yes/no) and diagnosed during hospital admission (yes/no). Likewise, days in hospital within 90 days from positive PCR test for CDI and time-to-treatment with vancomycin and FMT in all randomised patients will be compared in a linear regression model. Precision will be assessed by adjusting

- 368 for age \geq 85 years (yes/no) and diagnosed during hospital admission (yes/no) by performing linear regression
- analysis. If data are non-normally distributed, data will be logarithm-transformed in the regression model.
- 370 There will be no missing data on the primary outcome as these data are available from the EMRs. The num-
- ber of missing follow-up data on the secondary outcomes will be presented and we will perform a dropout analy-
- 372 sis of the data.
- All analyses will be performed in Stata version 17 (Stata Corp, Texas, USA).⁵⁷ The data will be monitored by
- an independent external monitoring institution.
- 375

376 Discussion

377 CDI constitutes a major health risk for frail older patients. The key challenge lies in conducting a personalised
378 early assessment and treatment approach for CDI. For this purpose, clinical evaluations and close monitoring of
379 the patient's condition are necessary.

In designing the CLODIFRAIL study, we prioritise investigating real-life scenarios. While the treatment will be individualised, our intention is to evaluate the intervention using stringent scientific methods. The project is innovative in aiming to improve care and treatment for all older patients with CDI in a real-life setting disregarding their mental or physical capability. This includes evaluating FMT in older frail patients who would otherwise be ineligible or unwilling to participate in randomised controlled trials of microbe-based therapeutics.⁵⁸

385 There are important limitations to the study. First, the participants will be old and multi-morbid and therefore 386 prone to experience new illnesses during the study period. This might make the intervention less effective. Sec-387 ond, the standard care may include elements of the intervention during the follow-up period (geriatric care and 388 FMT), making it less likely that the intervention will produce any effects. The patients and their relatives are not 389 blinded. Therefore, there is a risk that the research assistant might be unblinded if the participants reveal their 390 group allocation. Nor are the geriatricians participating in the study blinded, and those administering the inter-391 vention to patients may exhibit heightened attention their patients' treatment throughout the study period. Fi-392 nally, it is possible to validate the CDI diagnosis according to clinical symptoms only from data in the EMR as it 393 is not possible to contact the standard care group.

394 Because our intervention will address the concurrent frailty and clinical issues of each patient, it is important 395 to note that the intervention is not completely standardised. Interventions for geriatric patients are often com-396 plex.^{59,60} Describing the intervention with sufficient precision as to facilitate replication is a major challenge.⁶¹ 397 The CLODIFRAIL intervention includes several components. We chose the multi-component intervention as we 398 found it unethical and clinically questionable to assess patients for FMT without also giving them a CGA. For 399 that reason, we do not envisage these components to be disaggregated. It therefore makes sense to evaluate the 400 whole package of intervention. Consequently, pinpointing the specific components of the intervention that are 401 most effective may pose a challenge. To address this, we intend to compensate for this challenge by providing a 402 detailed description of the interventions that were implemented.

The geriatric intervention is extensive. Still, if it is effective, we argue that it can be conducted within the existing framework of an outgoing and multidisciplinary geriatric clinic. Alongside performing the study, we will

- 405 gain clinical knowledge on challenges in the treatment of older patients with CDI and implement a clinical
- 406 framework for home treatment with FMT in the ageing and health wards.

407

408 Trial status

- 409 The approved protocol with amendment number 4 was issued on 28 June 2022. The first patient was included on
- 410 01 September 2022. The study has finished recruiting patients at 3 May 2023.
- 411

412 List of abbreviations

- 413 CDI, Clostridioides difficile infection; CD, Clostridioides difficile; CDR, Central Denmark Region; CGA, Com-
- 414 prehensive Geriatric Assessment; EMR, Electronic medical record; EQ-5D-5L, 5-level EQ-5D version; FMT,
- 415 Faecal microbiota transplantation; FRS, Functional Recovery Score; MPI, Multidimensional Prognostic Index;
- 416 OQoL-DL, Overall Quality of Life Depression List; SPIRIT, Standard Protocol Items, Recommendations for
- 417 Interventional Trials

418 Declarations

419 *Ethical statement*

420 This study is conducted in accordance with the Helsinki Declaration.⁶² All patients receive, as a minimum, established standard medical care according to national clinical guidelines.⁴² In the study, we compare two established 421 422 organisational care pathways, i.e., a geriatric team assessment and the standard care of the attending team. The 423 study is conducted as a quality improvement study, embedded in two parallel and fundamentally different rou-424 tine clinical care pathways. It does not include experimental procedures or collection of biological specimens 425 other than those needed for clinical diagnostics and care planning. No patients will be exposed to any project-426 related risk or experimental treatments. Participants may decline parts of or the entire plan or treatment at any 427 time. According to Danish law, the study does therefore not fall under the jurisdiction of the Scientific Ethics 428 Committees. The study protocol was approved by the hospital board of directors at all participating hospitals. 429 Approval was obtained 14 March 2021. The study design and its categorisation as a quality improvement study 430 was approved by the Central Denmark Region Committees on Health Research Ethics (j.no. 1-10-72-1-21, 2 431 February 2021), following review of the complete study protocol. On publication, only anonymised and summa-432 rising data will be presented.

433 Permission to assess and transmit personal data from the EMRs relevant for quality improvement for patients 434 with CDI was obtained from the hospital boards at Aarhus University Hospital and all attending regional hospi-435 tals in the CDR. CD tests, conducted at the Department of Clinical Microbiology, AUH, are a part of the EMRs. 436 Thus, the project manager's permission to access the microbiological lists was granted via the same permission. 437 The CDR is the data protection responsible party. Personal data from the EMRs for quality improvement are 438 transferred to the research project at Aarhus University with a legal basis according to law, viz. the Data Protec-439 tion Act §10. Data will be managed via REDCap according to a cooperation agreement between Aarhus Univer-440 sity and the CDR.

By Danish law, consent to routine clinical treatment is given by oral and not written consent. All examinations and treatments in the study are conducted according to routine clinical practice and following obtaining informed oral consent, as required by the Danish Health Authority, under Danish law. In patients who do not have the capacity to provide oral consent, consent is given on behalf of the patient by a next of kin. All patients in the study are contacted by the geriatric team at 12 weeks of follow-up. Oral consent to perform QoL and functional status assessments is obtained and documented in the EMRs.

FMT treatment is provided following informed written consent, using a standardised FMT consent form (Ad-
ditional file 9). The patient's consent concerns permission for record access and data storage to allow full tracea-
bility according to the Tissue Act. Before FMT, the patient is informed orally and through a written information
leaflet about the effect and possible side effects.
Consent for publication
No personal information is published.
Availability of data and materials
No study data are available at the protocol stage of the project process. A code book for data entry databases and
all other project-related raw material are available upon reasonable request to the corresponding author.
Competing interests
The authors declare that they have no competing interests.
Funding
All funding embedded in routine care was obtained from the department of geriatrics, gastroenterology, and clin-
ical immunology at Aarhus university Hospital. The expenses related to the project that were not provided by
routine hospital funding, such as administrative personnel and PhD students, were covered by grants under the
clinical professor and chair at the Department of Geriatrics (EMD) and by the project leader (CH) of Centre for
Faecal Microbiota Transplantation (CEFTA), supported by the Health Research Foundation of the Central Den-
mark Region (grant number A2778) and Helsefonden (grant number 22-B-0239). The clinical safety board at
CEFTA approved the study protocol following internal peer review. Furthermore, independent professors at the
Aarhus University have peer reviewed the study protocol before acceptance of the protocol as a PhD study. The
FMT framework is supported by an investment from Innovation Fund Denmark (j.no. 8056-00006B). Christian
Lodberg Hvas has received project funding from the Novo Nordisk Foundation (j.no. NNF22OC0074080). The
design, management, analysis and reporting of the study are entirely independent of the funding sources.

Authors' contributions

- 476 TR*, HV*, MG*, MA*, IB*, JJ*, MR*, JR*, MØ*, RV*, CK*, CS*, SB*, CH* and ED* contributed to the de-
- 477 sign and planning of the study and have critically revised the manuscript. HV, RV and CS contributed to devel-
- 478 oping patient material. MG and CS provided statistical expertise. TR is responsible for the daily running of the
- 479 study, data collection and wrote the manuscript. All authors have approved the final manuscript. The authors fol-
- 480 low the ICMJE authorship guidelines. We made no use of professional writers.
- 481 *Tone Rubak (TR), Hanne Veilbæk (HV), Merete Gregersen (MG), Malene Asferg (MA), Ishay Barat (IB), Jo-
- 482 anna Secher Johnsen (JJ), Mikael Groth Riis (MR), Jeppe Rosenbæk (JR), Marianne Ørum (MØ), Rita Stock-
- 483 holm Vinding (RV), Carl Aksel Kragh Sørensen (CK), Claire J Steves (CS), Simon Mark Dahl Baunwall(SB),
- 484 Christian Lodberg Hvas (CH), Else Marie Skjøde Damsgaard (ED)
- 485
- 486 Acknowledgements
- 487 The authors thank all participating centres and patient representatives.


489	Figures and Tables legends
490	
491	Figure 1. CONSORT diagram. Patient flow.
492	Abbreviations: CDI: Clostridioides difficile infection; PCR: Polymerase chain reaction
493	
494	Figure 2. Standard Protocol Items Recommendations for Interventional Trials (SPIRIT) flow diagram figure
495	* All examinations and treatments in the intervention group are conducted according to routine clinical practice
496	and following obtaining informed oral consent, as required by the Danish Health Authority, in accordance with
497	Danish law.
498	**All patients in the intervention and standard care group are contacted by the geriatric team at 90 days of fol-
499	low-up, and oral consent to perform overall quality of life and functional status assessment is given and regis-
500	tered in the electronic medical journal.
501	
502	Figure 3. CLODIFRAIL intervention, flowchart.
503	Abbreviations: PCR: Polymerase chain reaction; CGA: Comprehensive geriatric assessment; MPI: Multidimen-
504	sional Prognostic Index; FMT: Faecal microbiota transplantation
505	
506	Figure 4. Clostridioides difficile infection, geriatric checklist
507	

508 References

- 1. Hensgens MP, Goorhuis A, Dekkers OM, van Benthem BH, Kuijper EJ. All-cause and disease-specific
- mortality in hospitalized patients with Clostridium difficile infection: a multicenter cohort study. *Clin Infect Dis* 2013; 56(8): 1108-16.
- 512 2. Khanna S, Lett J, Lattimer C, Tillotson G. Transitions of care in Clostridioides difficile infection: a need of
 513 the hour. *Therap Adv Gastroenterol* 2022; 15: 17562848221078684.
- 514 3. Bauer MP, Notermans DW, van Benthem BH, et al. Clostridium difficile infection in Europe: a hospital-515 based survey. *Lancet* 2011; **377**(9759): 63-73.
- 516 4. McGowan AP, Lalayiannis LC, Sarma JB, Marshall B, Martin KE, Welfare MR. Thirty-day mortality of
- 517 Clostridium difficile infection in a UK National Health Service Foundation Trust between 2002 and 2008. J
 518 Hosp Infect 2011; 77(1): 11-5.
- 5. Cober ED, Malani PN. Clostridium difficile infection in the "oldest" old: clinical outcomes in patients aged 520 80 and older. *J Am Geriatr Soc* 2009; **57**(4): 659-62.
- 521 6. Caupenne A, Ingrand P, Ingrand I, et al. Acute Clostridioides difficile Infection in Hospitalized Persons
- 522 Aged 75 and Older: 30-Day Prognosis and Risk Factors for Mortality. *J Am Med Dir Assoc* 2020; **21**(1): 110-4.
- 523 7. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. *Lancet* 2013; 381(9868):
 524 752-62.
- 525 8. Cunha AIL, Veronese N, de Melo Borges S, Ricci NA. Frailty as a predictor of adverse outcomes in
- bospitalized older adults: A systematic review and meta-analysis. Ageing Res Rev 2019; 56: 100960.
- 527 9. Govoni B, Zurlo A, De Giorgio R, Cultrera R, Volpato S. Clostridium difficile infection in a geriatric care unit: Clinical characteristics and prognosis. *JGG* 2021; 69(1): 1-5.
- 529 10. Olsen MA, Stwalley D, Demont C, Dubberke ER. Increasing Age Has Limited Impact on Risk of
- 530 Clostridium difficile Infection in an elderly population. *Open Forum Infect Dis* 2018; **5**(7): ofy160.
- 11. Inouye SK, Studenski S, Tinetti ME, Kuchel GA. Geriatric syndromes: clinical, research, and policy
 implications of a core geriatric concept. *J Am Geriatr Soc* 2007; 55(5): 780-91.
- 533 12. Cooper GS, Shlaes DM, Salata RA. Intraabdominal infection: differences in presentation and outcome
- between younger patients and the elderly. *Clin Infect Dis* 1994; **19**(1): 146-8.
- Fried LP, Storer DJ, King DE, Lodder F. Diagnosis of illness presentation in the elderly. *J Am Geriatr Soc*1991; **39**(2): 117-23.
- 537 14. Potts FEt, Vukov LF. Utility of fever and leukocytosis in acute surgical abdomens in octogenarians and
 beyond. *J Gerontol A Biol Sci Med Sci* 1999; 54(2): M55-8.
- 539 15. Leibovici-Weissman Y, Atamna A, Schlesinger A, Eliakim-Raz N, Bishara J, Yahav D. Risk factors for
- short- and long-term mortality in very old patients with Clostridium difficile infection: A retrospective study.
 Geriatr Gerontol Int 2017; 17(10): 1378-83.
- 542 16. Lauda-Maillen M, Liuu E, Catroux M, et al. Treatment compliance with European guidelines and prognosis
 543 of Clostridium difficile infection according to age. *Med Mal Infect* 2019; 49(3): 173-9.
- 544 17. Parker SG, McCue P, Phelps K, et al. What is Comprehensive Geriatric Assessment (CGA)? An umbrella
 545 review. *Age Ageing* 2018; 47(1): 149-55.
- 546 18. Ellis G, Gardner M, Tsiachristas A, et al. Comprehensive geriatric assessment for older adults admitted to
 547 hospital. *Cochrane Database Syst Rev* 2017; 9: Cd006211.
- 548 19. Pilotto A, Ferrucci L, Franceschi M, et al. Development and validation of a multidimensional prognostic
- 549 index for one-year mortality from comprehensive geriatric assessment in hospitalized older patients.
- 550 *Rejuvenation Res* 2008; **11**(1): 151-61.
- 20. Volpato S, Bazzano S, Fontana A, Ferrucci L, Pilotto A. Multidimensional Prognostic Index predicts
- mortality and length of stay during hospitalization in the older patients: a multicenter prospective study. J
 Gerontol A Biol Sci Med Sci 2015; **70**(3): 325-31.
- Ellis G, Whitehead MA, Robinson D, O'Neill D, Langhorne P. Comprehensive geriatric assessment for older
 adults admitted to hospital: meta-analysis of randomised controlled trials. *Bmj* 2011; 343: d6553.
- 556 22. Stuck AE, Siu AL, Wieland GD, Adams J, Rubenstein LZ. Comprehensive geriatric assessment: a meta 557 analysis of controlled trials. *Lancet* 1993; 342(8878): 1032-6.
- 558 23. Baztán JJ, Suárez-García FM, López-Arrieta J, Rodríguez-Mañas L, Rodríguez-Artalejo F. Effectiveness of
 acute geriatric units on functional decline, living at home, and case fatality among older patients admitted to
 hospital for acute medical disorders: meta-analysis. *Bmj* 2009; **338**: b50.
- 561 24. Rubenstein LZ, Stuck AE, Siu AL, Wieland D. Impacts of geriatric evaluation and management programs
- on defined outcomes: overview of the evidence. J Am Geriatr Soc 1991; **39**(9 Pt 2): 8S-16S; discussion 7S-8S.
- 563 25. Ellis G, Gardner M, Tsiachristas A, et al. Comprehensive geriatric assessment for older adults admitted to
 564 hospital. *Cochrane Database Syst Rev* 2017; 9(9): Cd006211.
- 565 26. Veronese N, Custodero C, Demurtas J, et al. Comprehensive geriatric assessment in older people: an
- umbrella review of health outcomes. *Age Ageing* 2022; **51**(5).

- 567 27. Pedersen LH, Gregersen M, Barat I, Damsgaard EM. Early geriatric follow-up visits to nursing home
- 568 residents reduce the number of readmissions: a quasi-randomised controlled trial. European Geriatric Medicine 569 2018; **9**(3): 329-37.
- 570 28. Pedersen LH, Gregersen M, Barat I, Damsgaard EM. Early geriatric follow-up after discharge reduces 571 readmissions – A quasi-randomised controlled trial. Eur Geriatr Med 2016; 7(5): 443-8.
- 572 29. Hansen TK, Pedersen LH, Shahla S, Damsgaard EM, Bruun JM, Gregersen M. Effects of a new early
- 573 municipality-based versus a geriatric team-based transitional care intervention on readmission and mortality
- 574 among frail older patients - a randomised controlled trial. Arch Gerontol Geriatr 2021; 97: 104511.
- 575 30. Pedersen LH, Gregersen M, Barat I, Damsgaard EM. Early geriatric follow-up after discharge reduces
- 576 mortality among patients living in their own home. A randomised controlled trial. Eur Geriatr Med 2017; 8(4): 577 330-6.
- 578 31. Baunwall SMD, Andreasen SE, Hansen MM, et al. Faecal microbiota transplantation for first or second
- 579 Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial. Lancet 580 Gastroenterol Hepatol 2022; 7(12): 1083-91.
- 581 32. Baunwall SMD, Lee MM, Eriksen MK, et al. Faecal microbiota transplantation for recurrent Clostridioides
- 582 difficile infection: An updated systematic review and meta-analysis. EClinicalMedicine 2020; 29-30:100642.
- 583 33. Rode AA, Chehri M, Krogsgaard LR, et al. Randomised clinical trial: a 12-strain bacterial mixture versus 584 faecal microbiota transplantation versus vancomycin for recurrent Clostridioides difficile infections. Aliment
- 585 Pharmacol and Ther 2021; 53(9): 999-1009.
- 586 34. Girotra M, Garg S, Anand R, Song Y, Dutta SK. Fecal microbiota transplantation for recurrent Clostridium 587 difficile infection in the elderly: long-term outcomes and microbiota changes. Dig Dis Sci 2016; 61(10): 3007-588 15.
- 589 35. Agrawal M, Aroniadis OC, Brandt LJ, et al. The long-term efficacy and safety of fecal microbiota transplant
- 590 for recurrent, severe, and complicated clostridium difficile infection in 146 elderly individuals. J Clin 591 Gastroenterol 2016; 50(5): 403-7.
- 592 36. Friedman-Korn T, Livovsky DM, Maharshak N, et al. Fecal transplantation for treatment of Clostridium 593 difficile infection in elderly and debilitated patients. Dig Dis Sci 2018; 63(1): 198-203.
- 594 37. Nivet C, Duhalde V, Beaurain M, Delobel P, Quelven I, Alric L. Fecal microbiota transplantation for 595 refractory Clostridioides difficile infection is effective and well tolerated even in very old subjects: a real-life 596 study. J Nutr Health Aging 2022.
- 597 38. Dahl Jørgensen SM, Mørck Rubak TM, Damsgaard EM, Dahlerup JF, Hvas CL. Faecal microbiota 598 transplantation as a home therapy to frail older people. Age Ageing 2020; 49(6): 1093-6.
- 599 39. Chan AW, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for 600 protocols of clinical trials. Bmj 2013; 346: e7586.
- 601 40. Jorgensen SMD, Hansen MM, Erikstrup C, Dahlerup JF, Hvas CL. Faecal microbiota transplantation:
- 602 establishment of a clinical application framework. Eur J Gastroenterol Hepatol 2017; 29(11): e36-e45.
- 603 41. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture
- 604 (REDCap)- a metadata-driven methodology and workflow process for providing translational research 605 informatics support. J Biomed Inform 2009; 42(2): 377-81.
- 606 42. Baunwall SMD, Dahlerup JF, Engberg JH, et al. Danish national guideline for the treatment of
- 607 Clostridioides difficile infection and use of faecal microbiota transplantation (FMT). Scand J Gastroenterol 608 2021; 56(9): 1056-77.
- 609 43. DSGH DsfGoH. Clostridioides Difficile infektion og fækal mikrobiota transplantation (FMT). 12/11/2020 610 2020. https://www.dsgh.dk/index.php/andre/c-diff-fmt (accessed 23/11/2020.
- 44. Keller JJ, Ooijevaar RE, Hvas CL, et al. A standardised model for stool banking for faecal microbiota 611
- 612 transplantation: a consensus report from a multidisciplinary UEG working group. United European
- 613 Gastroenterol J 2021; 9(2): 229-47.
- 614 45. Heggestad T, Lilleeng SE. Measuring readmissions: focus on the time factor. Int J Qual Health Care 2003; 615 15(2): 147-54.
- 616 46. EuroQol -a new facility for the measurement of health-related quality of life. Health Policy 1990; 16(3): 617 199-208.
- 618 47. Gregersen M, Jordansen MM, Gerritsen DL. Overall Quality of Life (OQoL) questionnaire in frail elderly: a
- 619 study of reproducibility and responsiveness of the Depression List (DL). Arch Gerontol Geriatr 2015; 60(1): 22-620 7.
- 621 48. Zuckerman JD, Koval KJ, Aharonoff GB, Skovron ML. A functional recovery score for elderly hip fracture
- 622 patients: II. Validity and reliability. J Orthop Trauma 2000; 14(1): 26-30.
- 623 49. Jensen CE, Sørensen SS, Gudex C, Jensen MB, Pedersen KM, Ehlers LH. The Danish EQ-5D-5L Value Set:
- 624 A Hybrid Model Using cTTO and DCE Data. Appl Health Econ Health Policy 2021; 19(4): 579-91.
- 625 50. Katz S, Downs TD, Cash HR, Grotz RC. Progress in development of the index of ADL. Gerontologist 1970; 626 10(1): 20-30.

- 627 51. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily
- 628 living. *Gerontologist* 1969; **9**(3): 179-86.
- 52. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in
 longitudinal studies: development and validation. *J Chronic Dis* 1987; 40(5): 373-83.
- 631 53. Hansen TK, Damsgaard EM, Shahla S, Bruun JM, Gregersen M. A reliable and record-based frailty
- assessment method for older medical inpatients. *Eur Geriatr Med* 2020; **11**(5): 803-12.
- 633 54. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection
- 634 in adults and children: 2017 update by the Infectious Diseases Dociety of America (IDSA) and Society for
- Healthcare Epidemiology of America (SHEA). *Clin Infect Dis* 2018; **66**(7): 987-94.
- 55. Hocquart M, Lagier JC, Cassir N, et al. Early Fecal Microbiota Transplantation Improves Survival in Severe
 Clostridium difficile Infections. *Clin Infect Dis* 2018; 66(5): 645-50.
- 638 56. Pocock SJ. When to stop a clinical trial. *Bmj* 1992; **305**(6847): 235-40.
- 538 56. Pocock SJ. When to stop a clinical trial. Bm_j 1992; **305**(6847): 235-40.
- 639 57. StataCorp. 2021. Stata Statistical Software: Release 17. College Station TSL. Stata Statistical Software:
- 640 Release 17. College Station, TX: StataCorp LLC; 2021.
- 58. Kelly CR, Fischer M, Grinspan A, Allegretti JR. Patients eligible for trials of microbe-based therapeutics do
 not represent the population with recurrent Clostridioides difficile infection. *Clin Gastroenterol Hepatol* 2020;
 18(5): 1099-101.
- 644 59. Saltvedt I, Mo ES, Fayers P, Kaasa S, Sletvold O. Reduced mortality in treating acutely sick, frail older
- patients in a geriatric evaluation and management unit. A prospective randomized trial. *J Am Geriatr Soc* 2002;
 50(5): 792-8.
- 647 60. Ellis G, Langhorne P. Comprehensive geriatric assessment for older hospital patients. *Br Med Bull* 2004; 71:
 648 45-59.
- 649 61. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex
- 650 interventions: the new Medical Research Council guidance. *Int J Nurs Stud* 2013; **50**(5): 587-92.
- 651 62. World Medical Association. WMA Declaration of Helsinki ethical principles for medical research
- 652 involving human subjects. 2022. <u>https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-</u>
- 653 principles-for-medical-research-involving-human-subjects/2024).



	STUDY PERIOD					
	Enrolmen t	Allocation	Post-a	Close-out		
TIMEPOINT**	-t ₁	0	Intervention	90 days	90 days	
ENROLMENT:						
Eligibility screen	Х					
Informed consent		X		X		
intervention						
Informed consent				X		
control*						
Non blinded	Х					
randomisation						
Allocation		X				
INTERVENTIO						
NS:						
Intervention group						
(geriatric		Х	Х			
assessment)						
Standard care		Х				
group						
ASSESSMENTS:						
Electronic						
medical records:						

Baseline variables	Х		
90 day survival		Х	Х
Time to treatment			
with FMT (FMT		Х	Х
date)			
Time to treatment			
with vancomycin			
(date of start		Х	Х
treatment with			
vancomycin)			
CDI recurrence		Х	Х
Readmission rate		Х	Х
Days in hospital		Х	Х
Trained research			
assistant			
Overall Quality of			
Life Depression		Х	Х
List (OQoL-DL)			
Overall Quality of	 		
Life EuroQol		\mathbf{v}	v
measurement		Х	Х
(version EQ-5D-			

5L Interviewer			
Administration			
Overall Quality of			
Life EuroQol			
measurement		Х	Х
(version EQ-5D-			
5L proxy 2)			
Functional status:			
Functional		Х	Х
recovery score		Λ	Λ
(FRS)			






Figure 4. Geriatric Clostridioides difficile infection – check list Patients with Clostridioides difficile infection (CDI) during hospital admission or at home.

Clostridium difficile infection (CDI) - definition:		
\geq 3 watery stools daily (Bristol stool chart \geq 6) + positive Clostridioides difficile PCR toxin test.		
	Done	Not
		relevant
1) CDI treatment care planning		
Describe CDI clinical status – use standard headlines (cdi1)		
Blood analyses (electrolytes, renal function, albumin, infectious parameters and haematological tests)		
Start vancomycin peroral or bactocin oral suspension (probe) 125 mg x 4.		
Continue vancomycin at least 10 days or until day before faecal microbiota transplantation (FMT).		
Perform the Multidimensional Prognostic Index		
Geriatric assessment of indication for Faecal Microbiota Transplantation (FMT) and treatment care		
planning.		
Deliver information material to the patient		
Deliver stool diary to the patient and/or primary caregivers.		
Corresponding letter to general practitioner, use standard headline (cdi2) + primary health care (cdi3)		
2) Medication review		
Antibiotics (other than vancomycin): discontinue if possible		
Antibiotics: consider preventive initiatives to avoid future use of antibiotics (e.g. Positive Expiratory		
Pressure device, vagifem treatment, sterile intermittent cathetherization etc.)		
Laxative: discontinue		
Proton pump inhibitor: discontinue if possible		
Diuretics: consider reduction during active diarrhoea (renal function)		
3) Rehydration and nutrition		
Nutrition: consider need for nutrition therapy and monitoring		
Rehydration therapy: consider need for rehydration therapy and monitoring		
Consider other reasons for diarrhoea! (e.g. inflammatory bowel disease, cancer, microscopic colitis)		
All patients have clinical contact to geriatric department during 8 weeks from date of last	FMT or	completed
vancomycin treatment.		
4) At termination (8 weeks)		
Clinical resolution: number of daily stools + Bristol scale.		
Stool PCR test for Clostridioides difficile		
Discharge summary for general practitioner – use standard headlines (cdi4)		
	-	

All activities are registered in the electronic medical journal.



Additional file 1. SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	ltem No	Description	Addressed on page number
Administrative inf	ormatior	ı	
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
	2b	All items from the World Health Organization Trial Registration Data Set	n/a
Protocol version	3	Date and version identifier	16
Funding	4	Sources and types of financial, material, and other support	18
Roles and	5a	Names, affiliations, and roles of protocol contributors	1, 5,7,18
responsibilities	5b	Name and contact information for the trial sponsor	n/a
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	18

5d Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee) 5-6

Introduction

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4-5		
	6b	Explanation for choice of comparators	4-5		
Objectives	7	Specific objectives or hypotheses	5		
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	5,7		
Methods: Participa	Methods: Participants, interventions, and outcomes				
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	5-6		
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	6		
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	7-10		
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	17		
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	9		
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	n/a		

Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	10-11
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	7-9, Figure 3
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	12-13
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	n/a
Methods: Assignm	ent of i	nterventions (for controlled trials)	
Allocation:			
Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	7
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	7
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	7
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	7
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	n/a

Methods: Data collection, management, and analysis

Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	11-12
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	n/a
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	12
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	13-14
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	13-14
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	14
Methods: Monitorir	ng		
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	n/a
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim _ results and make the final decision to terminate the trial	13
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse	n/a
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent	n/a


Ethics and dissemination


Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	17-18
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, _ analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	n/a
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and	17-18
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary _ studies, if applicable	n/a
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained _ in order to protect confidentiality before, during, and after the trial	17
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	18
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that _ limit such access for investigators	18
Ancillary and post- trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial _ participation	n/a
Dissemination policy	/ 31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	n/a
	31b	Authorship eligibility guidelines and any intended use of professional writers	19
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n/a
Appendices			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	17-18

Biological	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular	n/a
specimens		analysis in the current trial and for future use in ancillary studies, if applicable	

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "<u>Attribution-NonCommercial-NoDerivs 3.0 Unported</u>" license.

Additional file 2. Organisation chart for the study





Name (code)	Standard headlines			
CDI clinical status at first contact	Abdominal pain?			
(cdi1)	Number of stools per day?			
	Bristol type?			
	Faecal incontinence?			
	Loss of appetite?			
	Is the patient candidate for faecal microbiota			
	transplantation according to a geriatric assessment?			
	Plan:			
	The patient is affiliated with the Department of			
	Geriatrics the following 8 weeks because of			
	gastrointestinal infection with Clostridioides difficile.			
	Please contact Department of Geriatrics if indication			
	for antibiotics other than CDI related antibiotics.			
	Please contact Department of Geriatrics in case of			
	recurrent CDI.			
	Contact information ()			
Corresponding letter for primary	The patient is affiliated with the Department of			
health care (cdi2)	Geriatrics the following 8 weeks because of			
	gastrointestinal infection with Clostridioides difficile.			

Additional file 4. Standardised headlines for documenting Clostridioides difficile infection

	Please send weekly status of the following				
	(corresponding letters/telephone contact):				
	Abdominal pain? yes/no				
	Number of daily stools				
	Bristol type				
	Appetite?				
	Is the patient overall improving, status quo or				
	clinically worsening?				
	Please contact Department of Geriatrics if indication				
	for antibiotics other than CDI related antibiotics.				
	Please contact Department of Geriatrics in case of				
	increasing diarrhoea, abdominal pain or waning				
	general condition.				
	Contact information ()				
Corresponding letter for general	The patient is affiliated with the Department of				
practitioner (cdi3)	Geriatrics the following 8 weeks because of				
	gastrointestinal infection with Clostridioides difficile.				
	Please contact Department of Geriatrics if indication				
	for antibiotics other than CDI related antibiotics.				
	Please contact Department of Geriatrics in case of				
	increasing diarrhoea, abdominal pain or waning				
	general condition.				
	Contact information ()				

Discharge summary for general T	The patient has been affiliated with the Department				
Discharge summary for general T	The patient has been affiliated with the Department				
Discharge summary for general T	The patient has been affiliated with the Department				
	The patient has been affiliated with the Department				
practitioner (cdi4)	of Geriatrics because of gastrointestinal infection				
w	with Clostridioides difficile. The infection has been				
tr	treated with vancomycin and faecal microbiota				
tr	transplantation (date). Bowel movement has				
n	normalised (?).				
Т	The patient has an increased risk of recurrent				
C	Clostridioides difficile infection, especially when				
tr	treated with antibiotics other than CDI related				
a	antibiotics and/or treatment with proton pump				
in	nhibitors. In case of unexplained diarrhoea, we				
re	ecommend PCR toxin test for Clostridioides				
di	<i>lifficile</i> . If positive toxin test we recommend to start				
Va	vancomycin as soon as possible and referral to faecal				
m	microbiota transplantation. Feel free to contact us if				
in	n doubt.				
С	Contact information ()				
Faecal microbiotaT	The patient takes (number) of capsules within				
transplantation procedure (cdi5) (r	5) (minutes). Experiences no discomfort (?) and is				

observed in 30 minutes without acute complaints (?).				
Complications to treatment: (?)				
Clinical contact and follow-up via Department of				
Geriatrics. The patient and/or relatives and/or				
healthcare staff are informed of test stool kit which				
should be delivered as control test 8 weeks from				
today. Informed to continue to note stool frequency				
and gastrointestinal symptoms via stool diary. During				
the day after faecal microbiota transplantation				
procedure the patient may experience abdominal pain				
and loose stools. If fever or clinical worsening the				
patient is informed to contact the Department of				
Geriatrics (contact information).				

Additional file 5. Patient information material regarding *Clostridioides difficile* infection and treatment

Clostridioides Difficile infection and faecal microbiota transplantation

Clostridioides difficile is a bacterium that can cause serious infection of the intestine. In the elderly patient, where other illness has caused weakness, an infection with *Clostridioides difficile* can become serious. The infection tends to come back. What is typically experienced is numerous diarrhoea, nausea, reduced appetite, dehydration, fever, fatigue, weight loss and increased sadness. Some patients lose the will to live because of loss of energy.

We identify the infection using a stool sample supplemented with blood tests. Treatment is started with an antibiotic targeting the *Clostridioides difficile* bacterium following supply of healthy intestinal bacteria.

Faecal microbiota transplantation

Supply of healthy intestinal bacteria is also called faecal microbiota transplantation (FMT). There are no known side effects or late effects of FMT in patients who do not have other bowel disease. The healthy intestinal bacteria come from donors affiliated with the Department of Hepatology and Gastroenterology, Aarhus University Hospital. Strict requirements are placed on the donors equally to the Danish blood donor system. Donors are anonymous.

Faecal microbiota transplantation can take place in three ways:

- 1. via capsules taken orally over 30-45 minutes
- 2. via tube to the intestine
- 3. via endoscopy of the intestine (colonoscopy)

Regardless of which type you are offered, there will be clinical follow up contacts via the Department of Geriatrics.

Clinical follow-up contacts

Many older patients with *Clostridioides difficile* infection are severely weakened and need supportive treatment with fluids and nutrition including close monitoring of gastrointestinal symptoms. We offer clinical follow-up by staff trained in diseases in older patients. The purpose is to ensure an evaluation of the gastrointestinal symptoms and early start of treatment if indication for this.

How does the follow-up take place?

The follow-up involves a visit from the outgoing ageing and health ward team when you have received the diagnosis and a weekly telephone contact regarding evaluation of the gastrointestinal related symptoms. If there is a need for further visits, treatment or supportive therapy this will take place in your own home via the outgoing ageing and health ward teams.

What should I be aware of?

In case of changes in bowel movements, abdominal pain, nausea, reduced fluid intake/nutrition you/your relatives should contact Department of Geriatrics. In need of antibiotics other than the antibiotics used to treat CDI you must contact the Department of Geriatrics regarding treatment strategy because antibiotics can trigger a relapse of the infection. Transmission of the infection occurs with faeces and bacterial spores in the surroundings close to the patient. Handwash followed by hand disinfection must be carried out before leaving the patient. It important to use water/soap or

chloring alcohol. We recommend that health personnel ware plastic aprons and gloves to reduce infection transmission.

What are my responsibilities?

At termination we will ask you to deliver a stool sample to test for *Clostridioides difficile*. We will hand out a faeces kit and ask you to send/deliver it to Department of Microbiology.

Contact information

(...).



Additional file 6. Faecal microbiota transplantation home treatment - check list

Clostridium difficile infection (CDI) - definition:				
\geq 3 watery stools daily (Bristol stool chart \geq 6) + positive Clostridioides difficile PCR toxin test				
1) FMT – treatment planning				
Plan date for FMT and hand out patient preparation information material				
Patient consent form is to be completed by the patient				
Contact Center for Faecal Microbiota transplantation for capsules preparation				
2) FMT Procedure				
On the day of FMT collect capsules in freezer bag.				
The capsules must be used within 4 hours from start of thawing.				
The patient takes the FMT capsules within one hour with apple juice/ cola.				
Observe for 30 minutes after last capsule has been taken.				
3) FMT documentation				
Complete treatment leaflet and send copy to Center for Faecal Microbiota transplantation, <u>auh.cefta@rm.dk</u>				
Document FMT procedure in the electronic medical record using standard headline (cdi5)				
All patients have clinical contact to geriatric department during 8 weeks from date of last FMT.				
4) At termination (8 weeks)				
Clinical resolution: number of daily stools + Bristol scale.				

Stool PCR test for Clostridioides difficile

All activities are registered in the electronic medical journal.

Dear (patient label)

You have been offered and accepted treatment with faecal microbiota transplantation. The treatment consists of 15-25 capsules to be taken with apple juice or cola within one hour.

The treatment is performed by: (name of nurse/doctor) on the (date) / time Following preparations are needed: Fast from (time) on the (date) / . You are allowed to take liquids, but not dairy products until (time)_____ on the (date)_____. Vancomycin is terminated at (time) ______ at (date) ______. You have received tablet of Metoclopramide 10 mg which you are to take at (time)_____ on the (date) _____.

After the treatment (name of doctor/nurse) ______, we will be there for half an hour. After one hour you are allowed to eat/drink as usual. Some patients find that it takes a few hours before they feel hungry. You may experience loose stools, abdominal pain

within the first day. This is harmless and should resolve spontaneously. In case fever we advise you to contact us.

If you have any questions you are welcome to contact us: (contact info).

Additional file 8. Stool diary

Please write down daily. We will contact you and ask to your gastrointestinal symptoms to take stock of your clinical status.

Date	Abdominal pain (yes/no)	Number of stools per day	Bristol type	Loss of appetite? (yes/no)	Do you feel better? (yes/no)

Additional file 9. Faecal microbiota transplantation consent form

Information on fecal microbiota transplantation (FMT)

Center for Fecal Microbiota Transplantation (CEFTA)

Consent to quality assurance and research

You have agreed with your doctor to receive treatment with fecal microbiota transplantation (FMT). In order to investigate the quality and effects of the treatment, we need your consent. The aim is to gain a better understanding of how FMT works and to investigate the long-term consequences of treatment. The purpose is fulfilled through quality assurance and research. We ask for your consent to three things:

Consent to disclose health information

Information about your course is passed on to a database at Aarhus University. Only the researchers associated with the treatment have access to the database. All data is kept confidential and complies with the Personal Data Act and the European Personal Data Directive.

Consent to lookup in your patient record

After your treatment has ended, we would like to look up in your patient record to investigate any long-term consequences of the treatment. If we become aware that the treatment may pose a risk to you, we will contact you.

Consent for storage of samples for future research

There is still a lot we do not know about FMT. We therefore perform quality assurance and research to learn. All research projects are approved by the local Ethics Committee.

About the treatment

You will receive separate written patient instructions about the treatment. The written leaflet contains information on how the treatment takes place and the expected effect and any side effects.

About donor

Healthy faecal donors are found among blood donors. In order to be able to donate feces, a donor must undergo a study program

- Personal inquiry about medical history, previous or hereditary diseases, medication consumption

Questionnaire on risk of transmission of contagious diseases: travel abroad, tattoos, risk of infection with sexually transmitted diseases, etc.

- Blood tests with examination for infectious diseases and chronic diseases
- Stool sample with examination for infectious diseases and antibiotic resistance

A physician reviews all test results, and only approved donors provide stool for treatment.

Responsible for the treatment

Chief physician Christian Lodberg Hvas, Department of Hepatology and Gastroenterology, Aarhus University Hospital.

www.levermavetarm.auh.dk

Consent for fecal microbiota transplantation (FMT)

Center for Fecal Microbiota Transplantation (CEFTA)

Name and cpr

- 1. Consent to transfer gut-related health information to a database
- 2. Consent to follow-up by posting in your patient record at a later date
- 3. Consent for storage of samples for future research

"I hereby confirm that, having received the above written information, I know sufficiently about the purpose, advantages and disadvantages of giving this consent.

I know that participation is voluntary and that I can withdraw my commitment to participate at any time, after which my data will be deleted without affecting my current or future treatment options."

You have the right to a reflection period before you sign the consent form Information about your health conditions is subject to a duty of confidentiality and will only be available to doctors and nurses at the Department of Hepatology and Gastroenterology and the Blood Bank at Aarhus University Hospital. If data are passed on, it only happens in anonymised form.

Date Signature (patient)

Name of responsible doctor:

Name (responsible doctor)

Date Signature (responsible doctor)